FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2007658462> ?p ?o ?g. }

• W2007658462 abstract "Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, ILBackground: Pazopanib is a tyrosine kinase inhibitor targeting multiple receptors including vascular endothelial growth factor receptor, platelet derived growth factor receptor, and C-KIT and acts by inhibiting angiogenesis and tumor growth. Ixabepilone is a semi-synthetic analog of epothilone B and promotes microtubule stabilization inducing tumor cell apoptosis. The purpose of this study was to determine the optimal tolerated regimen (OTR) of combination pazopanib and ixabepilone during the first cycle of therapy for the treatment of advanced, previously treated solid tumor malignancies. Methods: Treatment was given until disease progression, unacceptable toxicity, or patient refusal. Ixabepilone was administered intravenously on day 1 of a 21-day cycle. Dose escalation started at 32 mg/m2 and increased to 40mg/m2. Pazopanib was administered orally once daily beginning on day 1 at a starting dose of 400mg and escalating at 200mg increments up to 800mg. Toxicity was assessed by using the Common Terminology Criteria for Adverse Events (version 3.0). Disease assessment was done every 2 cycles. Results: Twenty-eight patients (17 male and 11 female) with ECOG PS of 0 or 1 were enrolled from December 2009 to September 2011.The median age was 58 years (range 30-72). Primary tumor sites included lung (8), colon (9), skin (2), gallbladder (1), cholangiocarcinoma (1), neuroendocrine (1), head and neck (3), esophagus (1), small cell cancer (1), and leimyosarcoma (1). A total of 120 cycles of chemotherapy was administered with a median number of cycles per patient of 4 (range 1-13). Two dose-limiting toxicities (DLT) were seen including grade 4 neutropenia at dose level 2 (ixabepilone 40 mg/m2 and pazopanib 400 mg) and grade 4 thrombocytopenia with proteinuria at dose level 4 (ixabepilone 32 mg/m2 and pazopanib 800 mg). Dose level 2a was added to the study to confirm the safety of the proposed ixabepilone dose (32 mg/m2) before escalating the dose of pazopanib to levels 3 and 4. Dose level 3 was determined to be the optimal tolerated regimen (pazopanib 600 mg and ixabepilone 32 mg/m2). Grade 3-4 hematologic toxicities included neutropenia (14), febrile neutropenia (1), thrombocytopenia (2), and anemia (1). Grade 3-4 non-hematologic toxicities included weakness (1), dehydration (1), transaminitis (1), and fatigue (1). One patient withdrew from the study due to toxicity. Median time to progression during the study period was 3 months. Disease stabilization was seen in 11 patients and partial response in 5 patients. Conclusions: We were able to establish the OTR for combination of pazopanib and ixabepilone. Progression-free survival seen in patients with a variety of previously treated, advanced solid tumors warrants further investigation of this regimen.Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2762. doi:1538-7445.AM2012-2762" @default.
• W2007658462 created "2016-06-24" @default.
• W2007658462 creator A5023127032 @default.
• W2007658462 creator A5080267666 @default.
• W2007658462 creator A5085808365 @default.
• W2007658462 creator A5090069473 @default.
• W2007658462 date "2013-04-15" @default.
• W2007658462 modified "2023-10-14" @default.
• W2007658462 title "Abstract LB-158: Phase I study of pazopanib and ixabepilone in patients with solid tumors." @default.
• W2007658462 doi "https://doi.org/10.1158/1538-7445.am2013-lb-158" @default.
• W2007658462 hasPublicationYear "2013" @default.
• W2007658462 type Work @default.
• W2007658462 sameAs 2007658462 @default.
• W2007658462 citedByCount "0" @default.
• W2007658462 crossrefType "proceedings-article" @default.
• W2007658462 hasAuthorship W2007658462A5023127032 @default.
• W2007658462 hasAuthorship W2007658462A5080267666 @default.
• W2007658462 hasAuthorship W2007658462A5085808365 @default.
• W2007658462 hasAuthorship W2007658462A5090069473 @default.
• W2007658462 hasConcept C121608353 @default.
• W2007658462 hasConcept C126322002 @default.
• W2007658462 hasConcept C143998085 @default.
• W2007658462 hasConcept C197934379 @default.
• W2007658462 hasConcept C2775930923 @default.
• W2007658462 hasConcept C2777793932 @default.
• W2007658462 hasConcept C2778439243 @default.
• W2007658462 hasConcept C2779194965 @default.
• W2007658462 hasConcept C2779490328 @default.
• W2007658462 hasConcept C530470458 @default.
• W2007658462 hasConcept C71924100 @default.
• W2007658462 hasConcept C90924648 @default.
• W2007658462 hasConceptScore W2007658462C121608353 @default.
• W2007658462 hasConceptScore W2007658462C126322002 @default.
• W2007658462 hasConceptScore W2007658462C143998085 @default.
• W2007658462 hasConceptScore W2007658462C197934379 @default.
• W2007658462 hasConceptScore W2007658462C2775930923 @default.
• W2007658462 hasConceptScore W2007658462C2777793932 @default.
• W2007658462 hasConceptScore W2007658462C2778439243 @default.
• W2007658462 hasConceptScore W2007658462C2779194965 @default.
• W2007658462 hasConceptScore W2007658462C2779490328 @default.
• W2007658462 hasConceptScore W2007658462C530470458 @default.
• W2007658462 hasConceptScore W2007658462C71924100 @default.
• W2007658462 hasConceptScore W2007658462C90924648 @default.
• W2007658462 hasLocation W20076584621 @default.
• W2007658462 hasOpenAccess W2007658462 @default.
• W2007658462 hasPrimaryLocation W20076584621 @default.
• W2007658462 hasRelatedWork W1975041356 @default.
• W2007658462 hasRelatedWork W1995668258 @default.
• W2007658462 hasRelatedWork W1999260523 @default.
• W2007658462 hasRelatedWork W2022138045 @default.
• W2007658462 hasRelatedWork W2041903407 @default.
• W2007658462 hasRelatedWork W2049880080 @default.
• W2007658462 hasRelatedWork W2065780317 @default.
• W2007658462 hasRelatedWork W2076487518 @default.
• W2007658462 hasRelatedWork W2125689364 @default.
• W2007658462 hasRelatedWork W2131491065 @default.
• W2007658462 hasRelatedWork W2144956922 @default.
• W2007658462 hasRelatedWork W2148829218 @default.
• W2007658462 hasRelatedWork W2247131005 @default.
• W2007658462 hasRelatedWork W2323783599 @default.
• W2007658462 hasRelatedWork W2477879802 @default.
• W2007658462 hasRelatedWork W2560857104 @default.
• W2007658462 hasRelatedWork W2591413386 @default.
• W2007658462 hasRelatedWork W2607124727 @default.
• W2007658462 hasRelatedWork W2835940100 @default.
• W2007658462 hasRelatedWork W3019726983 @default.
• W2007658462 isParatext "false" @default.
• W2007658462 isRetracted "false" @default.
• W2007658462 magId "2007658462" @default.
• W2007658462 workType "article" @default.